AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
15 déc. 2023 07h22 HE
|
AC Immune SA
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of...
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease
18 janv. 2023 07h00 HE
|
AC Immune SA
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease First Alzheimer’s patient imaged with PI-2620 in ADvance, the pivotal Phase 3...
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
30 nov. 2022 07h00 HE
|
AC Immune SA
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development Data presented at CTAD 2022 confirm excellent clinical performance of ACI-35.030 vaccine candidateBased...
AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference
23 nov. 2022 07h30 HE
|
AC Immune SA
Next generation SupraAntigen® liposomal vaccine platform augments immunization against pathological targets of Alzheimer’s diseaseNew data on anti-phospho-Tau vaccines confirm safety, tolerability and...
Amydis Receives NIH Grant Award to Develop a Novel Tau Retinal Tracer for Alzheimer's Diseases and other Tauopathies
02 sept. 2021 07h00 HE
|
Amydis, Inc.
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...
Voyager Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Highlights
07 août 2018 16h07 HE
|
Voyager Therapeutics, Inc.
Clinical data updates and regulatory feedback for VY-AADC during the quarter support planned pivotal program for Parkinson’s disease Pipeline programs progressing with updated preclinical data from...
Voyager Therapeutics Announces First Quarter 2018 Financial Results and Corporate Highlights
10 mai 2018 07h04 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
SENS Research Foundation Announces New Research Program on Age-Related Neurodegeneration With Buck Institute for Research on Aging
06 févr. 2017 11h00 HE
|
SENS Research Foundation
MOUNTAIN VIEW, CA--(Marketwired - February 06, 2017) - The SENS Research Foundation (SRF) has launched a new research program in collaboration with the Buck Institute for Research on Aging. Dr. Julie...